Maoxing Bio Announces 80% ORR with Off-the-Shelf IL-13Rα2-Targeted CAR-T MT026 in Recurrent High-Grade Glioma

Suzhou Maoxing Biotechnology Co., Ltd. Kicks Off 2026 with Promising News for the Universal CAR-T Field.

First, in December 2025, the FDA approved B7H3-targetedGeneral TypeInitiation of CAR-T Cell MT027ⅡPhase Clinical Study; Then, January 22, 2026MT026, a Universal CAR-T Cell Targeting IL-13Rα2, Reports Positive First Clinical Data.

Today (January 22, 2026),Suzhou Maoxing Biotechnology Co., Ltd. announced that itsIL-13Rα2-Targeted Universal CAR-T Cell Therapy MT026 for Recurrent High-Grade GliomaⅠPhase Clinical Research Data, Published Online onInternationally Renowned Academic JournalsNature Communications。

It is worth noting that this isThe first human clinical data of MT026 was disclosed.

According toNature CommunicationsThe published article shows,In the 5 cases enrolledRecurrent High-Grade GliomaAmong the patients, an 80% objective response rate was observed, including 1 complete response and 3 partial responses.The median overall survival of patients reached 13.1 months from the time of tumor recurrence and enrollment.

In terms of safety, no treatment-related adverse events of grade ≥3, severe cytokine release syndrome, neurotoxicity, or graft-versus-host disease occurred throughout the treatment process, demonstrating significant safety characteristics.

In addition, in December 2025, Suzhou Maoxing Biotechnology Co., Ltd.B7H3-Targeted Universal CAR-T Cell Therapy MT027 Receives FDA Approval for Phase II Clinical Study to Treat Recurrent Glioblastoma (rGBM).

MT027It is an "off-the-shelf" UCAR-T cell therapy product targeting B7H3 derived from healthy donors. According toPublic information shows,MT027 adopts a non-viral gene editing process. Compared with viral vector technology, non-viral technology mayFurther enhance the safety of the product and improve the precision and controllability of the preparation process.

MT027 isThe core pipeline of Suzhou Maoxing Biotechnology Co., Ltd., the leading indication isGlioblastoma, concurrently advancing treatments for brain metastatic tumors, abdominal metastatic tumors,The development of various indications such as thoracic vertebral mesothelioma.

It is worth noting that,MT027 Receives FDA Approval for AdvancementPhase II Clinical Trial, MarksMT027 has become one of the fastest progressing B7H3 CAR-T projects globally.

Further Reading:The Most Advanced B7H3 CAR-T

In fact, since the rise of in vivo CAR-T, universal CAR-T, as the next-generation CAR-T direction, has to some extent fallen out of favor — by 2025, multiple collaborations on allogeneic cells have been terminated in the global market.

And focus on universal CAR-TSuzhou Maoxing Biotechnology Co., Ltd.'s two consecutive pieces of good news have boosted the somewhat sluggish universal CAR-T field.

References:

1.Suzhou Maoxing Biotechnology Co., Ltd.《Universal CAR-T Achieves Breakthroughs! Suzhou Maoxing Biotechnology's MT026 Clinical Data Published in Nature Sub-Journal, MT027 Approved for Phase II Clinical Trial in the U.S.》

·

·